|
US2020369759A1
|
|
Methods of treatment of muscular dystrophies
|
|
US2019127456A1
|
|
Methods of treating idiopathic pulmonary fibrosis
|
|
EP3386544A1
|
|
Methods for treatment of motor neuron diseases
|
|
US2015210760A1
|
|
Therapeutic method for pancreatic cancer
|
|
KR20160018514A
|
|
Pharmaceutical formulations of a hif hydroxylase inhibitor
|
|
TW201518279A
|
|
Crystalline forms of a prolyl hydroxylase inhibitor
|
|
CA2899024A1
|
|
Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
|
|
KR20150058147A
|
|
Process for making isoquinoline compounds
|
|
US2014024675A1
|
|
Crystalline forms of a prolyl hydroxylase inhibitor
|
|
WO2014014835A2
|
|
Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
|
|
EP2844291A1
|
|
Methods for treating idiopathic pulmonary fibrosis
|
|
US2015147340A1
|
|
Therapeutic methods for peritoneal carcinomatosis
|
|
CA2866556A1
|
|
4 -hydroxy-isoquinoline compounds as hif hydroxylase inhibitors
|
|
CN104427980A
|
|
Treatment for high cholesterol
|
|
WO2013070908A1
|
|
Therapeutic method
|
|
US2014065162A1
|
|
Compositions and Methods for Treating Brain Tumors
|
|
CN103608346A
|
|
Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
|
|
WO2012100262A1
|
|
Therapeutic method using anti - ctgf antibody
|
|
CN103429240A
|
|
Methods for increasing mean corpuscular volume
|
|
WO2012097331A1
|
|
Methods for increasing reticulocyte hemoglobin content
|
